



MEMORANDUM

TO: CIRM GOVERNING BOARD
FROM: BENJAMIN HUANG, Associate General Counsel
SUBJECT: IP Summary for Shizuru DR2 Grant
DATE: FEBRUARY 2019

Dr. Shizuru has licensed her combination technology from her current CIRM grant using anti-CD117 antibodies in connection with other therapies. Under the CIRM IP regulations in place at the time when the DR2 grant was awarded, there are revenue sharing obligations to the State of California which are dependent on the amount Stanford University receives from such license(s).

The SCID-focused work, the subject of the current application for funding, is addressed in the attached confidential commercialization plan (Exhibit A) submitted to CIRM by the applicant. If the application is approved, such work will have revenue-sharing obligations from Stanford from the existing DR2 grant and also royalty revenue sharing obligations from the eventual Commercializing Entity from the new grant (due to subsequent changes in the CIRM intellectual property regulations that would apply to the new application if funded).

Attachments:

- A: Confidential Commercialization Plan
- B: Confidential CIRM Legal Summary